About Cabling Installation & Maintenance

Our mission: Bringing practical business and technical intelligence to today's structured cabling professionals

For more than 30 years, Cabling Installation & Maintenance has provided useful, practical information to professionals responsible for the specification, design, installation and management of structured cabling systems serving enterprise, data center and other environments. These professionals are challenged to stay informed of constantly evolving standards, system-design and installation approaches, product and system capabilities, technologies, as well as applications that rely on high-performance structured cabling systems. Our editors synthesize these complex issues into multiple information products. This portfolio of information products provides concrete detail that improves the efficiency of day-to-day operations, and equips cabling professionals with the perspective that enables strategic planning for networks’ optimum long-term performance.

Throughout our annual magazine, weekly email newsletters and 24/7/365 website, Cabling Installation & Maintenance digs into the essential topics our audience focuses on.

  • Design, Installation and Testing: We explain the bottom-up design of cabling systems, from case histories of actual projects to solutions for specific problems or aspects of the design process. We also look at specific installations using a case-history approach to highlight challenging problems, solutions and unique features. Additionally, we examine evolving test-and-measurement technologies and techniques designed to address the standards-governed and practical-use performance requirements of cabling systems.
  • Technology: We evaluate product innovations and technology trends as they impact a particular product class through interviews with manufacturers, installers and users, as well as contributed articles from subject-matter experts.
  • Data Center: Cabling Installation & Maintenance takes an in-depth look at design and installation workmanship issues as well as the unique technology being deployed specifically for data centers.
  • Physical Security: Focusing on the areas in which security and IT—and the infrastructure for both—interlock and overlap, we pay specific attention to Internet Protocol’s influence over the development of security applications.
  • Standards: Tracking the activities of North American and international standards-making organizations, we provide updates on specifications that are in-progress, looking forward to how they will affect cabling-system design and installation. We also produce articles explaining the practical aspects of designing and installing cabling systems in accordance with the specifications of established standards.

Cabling Installation & Maintenance is published by Endeavor Business Media, a division of EndeavorB2B.

Contact Cabling Installation & Maintenance

Editorial

Patrick McLaughlin

Serena Aburahma

Advertising and Sponsorship Sales

Peter Fretty - Vice President, Market Leader

Tim Carli - Business Development Manager

Brayden Hudspeth - Sales Development Representative

Subscriptions and Memberships

Subscribe to our newsletters and manage your subscriptions

Feedback/Problems

Send a message to our general in-box

 

Bright Minds Biosciences Stock Surges Almost 1,500%

Bright Minds Biosciences Stock

Bright Minds Biosciences (NASDAQ: DRUG), a little-known biotech company, became the talk of the market yesterday after its stock skyrocketed by 1,445% in a single trading session. Typically trading under 1 million shares daily, the stock saw over 100 million shares change hands without any direct news. So, what drove this extraordinary rally, and should investors take note?

What is Bright Minds Biosciences?

Founded in 2017 and headquartered in New York, Bright Minds Biosciences focuses on developing therapeutics for severe neurological and psychiatric disorders. The company’s pipeline includes selective 5-HT receptor agonists aimed at treating epilepsy, pain, and mental health conditions. Its leading candidate, BMB-101, targets serotonin receptors (5-HT2C) to influence brain functions, with promising potential in epilepsy.

Bright Minds is also working on BMB-202 to address depression, anxiety, and PTSD, and BMB-201 to treat anxiety disorders. Collaborations with institutions such as the National Institutes of Health, the University of Texas Medical Branch, and the Medical College of Wisconsin further bolster its research efforts.

Why Did DRUG Surge?

Several factors contributed to the dramatic surge. One major catalyst was recent M&A activity in the industry, with LBPH's lead drug LP352 (similar to Bright Minds' BMB-101) being acquired at a substantial premium just two days earlier. This event triggered increased interest in DRUG as investors speculated on the potential value of Bright Minds' pipeline.

Technical factors also played a crucial role in fueling the rally. With only 2.5 million shares in the float, the stock became vulnerable to a massive short squeeze. The availability of shares for shorting (locates) across trading platforms at low borrowing costs added to the momentum. As short sellers were forced to buy back shares to cover their positions amid the sudden surge in demand, the stock price skyrocketed further in a textbook short squeeze.

Key Updates for BMB-101

Bright Minds' flagship drug, BMB-101, has shown positive developments. The company recently completed a Phase 1 clinical trial, demonstrating the drug is safe and well-tolerated in healthy participants. A Phase 2 trial began in September 2024, with results expected within 18-20 weeks.

The company will also be active at several biotech conferences to present its progress. Key upcoming events include BIO-Europe in Stockholm from November 4-6, the Chicago Biocapital Summit from November 6-7, and the AES Annual Meeting in Los Angeles from December 6-10, where Bright Minds will present data on BMB-101’s use in treating rare epilepsies. Financially, the company is well-positioned, with enough cash to fund operations through 2026, though additional equity financing is likely.

Should You Invest?

The recent surge has attracted widespread attention, but whether to invest depends heavily on your risk appetite. The stock's volatility, low liquidity, and sharp price swings make it a risky bet for long-term investors. DRUG may be more suitable for short-term traders who can exploit its intraday movements.

However, with its small float and trading inefficiencies, the stock will likely remain highly volatile as long as interest persists. While the potential for further gains exists, so does the risk of sharp declines, making it a high-risk, high-reward play for speculative traders.

Stock Quote API & Stock News API supplied by www.cloudquote.io
Quotes delayed at least 20 minutes.
By accessing this page, you agree to the following
Privacy Policy and Terms Of Service.